![]() |
市场调查报告书
商品编码
1889469
手术机器人市场预测至2032年:按产品、应用、控制机制、最终用户和地区分類的全球分析Surgical Robot Market Forecasts to 2032 - Global Analysis By Offering (Robotic Systems, Instruments & Accessories, Software & Analytics, and Services), Application, Control Mechanism, End User, and By Geography |
||||||
根据 Stratistics MRC 的研究,预计到 2025 年,全球手术机器人市场价值将达到 95 亿美元,到 2032 年将达到 298 亿美元。
预计在预测期内,手术机器人市场将以17.7%的复合年增长率成长。手术机器人市场涵盖机器人系统、器械和软体,旨在辅助外科医生进行微创手术。这些设备广泛应用于泌尿系统、妇科、一般外科、整形外科和神经外科等专科。其优势包括更高的手术精度、更佳的视野、在狭小空间内更便捷的操作、更小的切口带来的出血量减少、更短的住院时间和更快的患者康復。同时,医疗机构也能从中受益,提高手术的一致性,并增强自身的竞争优势。
根据 Intuitive Surgical 的文件和公开声明,该公司预计在 2023 年安装约 1370 台达文西手术系统,到 2023 年底,其安装量将超过 8600 台,这表明其机器人手术平台将继续扩张。
扩大微创手术的应用
手术机器人市场的主要驱动力之一是全球微创手术的加速发展。这些系统能够透过较小的切口进行手术,从而显着减轻患者的身体负担,减少出血量,缩短住院时间,进而直接降低整体医疗成本并改善患者预后。随着外科医生和患者对这些优势的认识不断加深,泌尿系统和妇科等专科对机器人辅助手术技术的需求激增,迫使医院投资这项技术以保持竞争力并满足临床需求。
极高的资本和营运成本
手术机器人带来的沉重经济负担严重阻碍了其市场扩张。医院购置初始系统需要数百万美元的资本投入。此外,持续营运费用还包括昂贵的专用设备、强制性维护合约以及针对手术人员的大规模培训项目。这一巨大的经济障碍限制了手术机器人的普及,尤其是在对成本高度敏感的地区以及医疗预算有限的发展中地区。因此,高昂的总拥有成本仍是限制市场渗透的主要因素。
开发经济高效的系统
目前,新参与企业和现有企业都致力于建立针对特定外科手术和中型医院的价值工程系统。这项策略旨在普及机器人手术,并挖掘尚未开发的市场和门诊手术中心的潜在需求。该领域的成功不仅能够扩大基本客群,还可能加剧市场竞争,并刺激整个市场的进一步创新和价格调整。
监管障碍和核准延误
目前,新参与企业和现有企业都致力于建造针对特定手术和中型医院设计的价值工程系统。这项策略旨在普及机器人手术,并释放尚未开发的市场和门诊手术中心的潜在需求。该领域的成功不仅能够扩大基本客群,还可能加剧市场竞争,并刺激整个市场的进一步创新和价格调整。
疫情初期,全球医疗系统为节约资源、控制感染风险而延后非紧急手术,导致医疗服务严重衝击。这造成采用机器人辅助系统进行的择期手术数量大幅下降。然而,这场危机也凸显了自动化技术和微创手术在缩短住院时间和减少病患接触方面的价值。随着手术量的增加,对机器人手术平台的需求也随之增长,从而提高了医院的运作效率。这使得市场在疫情初期过后迅速復苏。
预计在预测期内,机器人系统细分市场将占据最大的市场份额。
预计在预测期内,机器人系统领域将占据最大的市场份额,因为每套新安装的系统都需要销售一套高价值的完整系统。技术的不断进步,包括先进成像和数据分析技术的集成,正在推动系统的升级和新购买。此外,随着新的医院和手术中心进入机器人手术领域,它们的初始投资也集中于此核心硬件,从而巩固了该领域在可预见的未来作为主要收入来源的地位。
预计在预测期内,整形外科和关节重建手术领域将达到最高的复合年增长率。
受全球骨关节炎患病率上升以及老龄化人口对膝关节和髋关节重建手术需求增加的推动,整形外科和关节置换手术领域预计将在预测期内实现最高增长率。机器人系统在骨骼准备和植入定位方面具有无与伦比的精准度,这对于改善关节功能和确保手术长期成功至关重要。机器人系统在实现稳定且可重复的手术结果方面已证实具有显着的临床优势,这促使骨科医生迅速采用这项技术,从而推动了其强劲的成长势头。
预计北美将在预测期内占据最大的市场份额,这主要得益于其完善的医疗基础设施、高昂的医疗支出以及对先进医疗技术的早期和广泛应用。美国对机器人手术的支持性报销政策以及主要市场参与者的强大影响力进一步巩固了其主导地位。该地区完善的法规结构也促进了新系统的快速商业化,并确保先进临床中心能够持续获得创新产品。
预计亚太地区在预测期内将实现最高的复合年增长率,这主要得益于中国、印度和日本等国医疗体系的快速发展、医疗旅游业的增长以及医院基础设施现代化投资的增加。此外,庞大且老化的人口基数也对先进的外科手术服务产生了显着需求。该地区的公立和私立医院越来越重视机器人系统,将其视为提升服务水准和增强全球竞争力的策略性投资。
According to Stratistics MRC, the Global Surgical Robot Market is accounted for $9.5 billion in 2025 and is expected to reach $29.8 billion by 2032, growing at a CAGR of 17.7% during the forecast period. The surgical robot market covers robotic systems, instruments, and software that assist surgeons in performing minimally invasive procedures. It serves specialties such as urology, gynecology, general surgery, orthopedics, and neurosurgery. Benefits include enhanced precision, better visualization, improved dexterity in confined spaces, and smaller incisions that can reduce blood loss, shorten hospital stays, and support faster patient recovery, while hospitals gain from higher procedural consistency and competitiveness.
According to Intuitive Surgical company filings and public statements, Intuitive placed ~1,370 da Vinci surgical systems in 2023 and the installed base exceeded 8,600 systems by end-2023, illustrating continuing scale-up of robotic surgery platforms.
Growing Adoption of Minimally Invasive Surgery
The primary catalyst for the surgical robot market is the accelerating global shift towards minimally invasive procedures. These systems facilitate surgeries through small incisions, leading to significantly reduced patient trauma, less blood loss, and shorter hospital stays. This directly translates to lower overall healthcare costs and improved patient outcomes. As both surgeons and patients become more aware of these benefits, demand for robotic-assisted techniques in specialties like urology and gynecology is surging, compelling hospitals to invest in this technology to remain competitive and meet clinical demand.
Extremely High Capital and Operational Costs
The profound financial burden associated with surgical robots severely hinders market expansion. The initial purchase of a system represents a multi-million-dollar capital investment for hospitals. Furthermore, ongoing operational expenses include costly proprietary instruments, mandatory maintenance contracts, and extensive training programs for surgical staff. This significant financial barrier restricts adoption, especially in cost-sensitive settings and developing regions with constrained healthcare budgets. Consequently, the high total cost of ownership remains a major factor slowing broader market penetration.
Development of Cost-Effective Systems
New market entrants and established players are now focusing on creating value-engineered systems tailored for specific procedures or mid-tier hospitals. This strategy aims to democratize access to robotic surgery, unlocking latent demand in untapped markets and outpatient surgical centers. Success in this area would not only expand the customer base but also intensify competition, potentially driving further innovation and price adjustments across the entire market landscape.
Regulatory Hurdles and Approval Delays
New market entrants and established players are now focusing on creating value-engineered systems tailored for specific procedures or mid-tier hospitals. This strategy aims to democratize access to robotic surgery, unlocking latent demand in untapped markets and outpatient surgical centers. Success in this area would not only expand the customer base but also intensify competition, potentially driving further innovation and price adjustments across the entire market landscape.
The pandemic initially caused significant disruption, as healthcare systems worldwide deferred non-essential surgical procedures to conserve resources and manage infection risks. This led to a notable decline in elective surgeries performed with robotic systems. However, the crisis also underscored the value of automation and minimally invasive techniques in potentially reducing hospital stays and minimizing patient contact. As the number of surgeries increased, the demand for robotic platforms grew, and hospitals became more efficient. This helped the market recover quickly after the first phase.
The robotic systems segment is expected to be the largest during the forecast period
The robotic systems segment is expected to account for the largest market share during the forecast period because each new installation requires the sale of a complete, high-value system. The continuous technological evolution, including the integration of advanced imaging and data analytics, encourages upgrades and new purchases. Furthermore, as new hospitals and surgical centers enter the robotic surgery field, their initial investment is in this core hardware, securing this segment's position as the primary revenue generator for the foreseeable future.
The orthopedic & joint replacement surgery segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the orthopedic & joint replacement surgery segment is predicted to witness the highest growth rate, driven by a rising global prevalence of osteoarthritis and an aging population requiring procedures like knee and hip replacements. Robotic systems provide unparalleled precision in bone preparation and implant positioning, which is crucial for improving joint function and the longevity of these surgeries. The demonstrated clinical benefits in achieving consistent, reproducible outcomes are compelling orthopedic surgeons to rapidly adopt this technology, fueling its exceptional growth rate.
During the forecast period, the North America region is expected to hold the largest market share, anchored by a robust healthcare infrastructure, high healthcare expenditure, and early, widespread adoption of advanced medical technologies. Supportive reimbursement policies for robotic procedures in the U.S. and the strong presence of leading market players further consolidate its leading position. The region's well-established regulatory framework also facilitates quicker commercialization of new systems, ensuring a continuous pipeline of innovative products for its advanced clinical centers.
During the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, fueled by rapidly improving healthcare systems, growing medical tourism, and increasing investments in modernizing hospital infrastructure in countries like China, India, and Japan. Moreover, the large and aging population base is creating substantial demand for advanced surgical care. Governments and private hospitals in the region are increasingly viewing robotic systems as a strategic investment to enhance their service offerings and competitive stature on the global stage.
Key players in the market
Some of the key players in Surgical Robot Market include Intuitive Surgical, Inc., Stryker Corporation, Medtronic plc, Johnson & Johnson, Zimmer Biomet Holdings, Inc., Smith & Nephew plc, Siemens Healthineers AG, Renishaw plc, CMR Surgical Ltd, Globus Medical, Inc., Asensus Surgical, Inc., THINK Surgical, Inc., Vicarious Surgical Inc., and Medrobotics Corporation.
In October 2025, CMR announced plans to integrate AI via collaboration with NVIDIA to make surgical robotics smarter (leveraging data from every Versius procedure).
In October 2024, CMR Surgical received U.S. regulatory clearance (de novo) for its Versius system for gallbladder removal enabling U.S. use of its robotic surgery platform.
In August 2024, Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that it has signed a strategic development agreement with the LSU Health New Orleans.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.